# RetinAI

其基于 AI 的 OCT 分析平台（RetinAI Discovery）已被 EssilorLuxottica 收购——该交易于2025年10月被报道——使该技术被纳入规模远大于自身的眼健康与眼镜业务体系。

Source: https://cn.bioecon.ru/companies/retinai/
Updated: 2026-07-20

- 国家: Switzerland

## 可核验事实

| 事实 | 数值 | 来源 |
| --- | --- | --- |
| 融资 | 3轮累计融资$15.7 million | https://www.thecompanycheck.com/company/b/retinai-medical/bq1iaae4wr5qtglwr |
| 员工人数 | 截至2025年10月，员工超过60人 | https://www.unibe.ch/innovation/stories_and_startups/innovation_stories/retinai___ikerian/index_eng.html |
| 认证 | 根据欧盟医疗器械法规MDR 2017/745，多款AI模型和平台（包括RetinAI OCT Atlas）已获CE标志用于临床使用 | https://www.retinai.com/, https://www.retinai.com/press-releases/essilorluxottica-acquires-retinai-accelerating-transformative-ai-and-data-powered-eye-health-solutions, https://www.retinai.com/press-releases/retinai-oct-atlas-r-is-now-ce-marked-for-clinical-use-one-algorithm-for-amd-dr-dme-and-glaucoma |
| 监管批准 | 获得 FDA 510(k) 许可的平台（RetinAI Discovery） | https://glance.eyesoneyecare.com/stories/2025-10-23/essilorluxottica-purchases-retinai/, https://www.retinai.com/press-releases/essilorluxottica-acquires-retinai-accelerating-transformative-ai-and-data-powered-eye-health-solutions, https://www.retinai.com/press-releases/retinai-oct-atlas-r-is-now-ce-marked-for-clinical-use-one-algorithm-for-amd-dr-dme-and-glaucoma |
| 总部 | 瑞士伯尔尼 | https://www.retinai.com/press-releases/essilorluxottica-acquires-retinai-accelerating-transformative-ai-and-data-powered-eye-health-solutions |
| 生产基地 | 瑞士伯尔尼（Bern，总部）和美国波士顿（Boston，子公司） | https://www.retinai.com/press-releases/essilorluxottica-acquires-retinai-accelerating-transformative-ai-and-data-powered-eye-health-solutions |

独立来源: glance.eyesoneyecare.com, thecompanycheck.com, unibe.ch

## 技术

- [AI 光学相干断层扫描筛查](https://cn.bioecon.ru/technology/ai-optical-coherence-tomography-screening/)